伊诺维奥制药 INO 深 沪
已收盘 12-31 16:00:00 美东时间
1.74
-0.020
-1.14%
华盛通- 最 高1.855
- 今 开1.77
- 成交量 135.44万股
- 最 低 1.73
- 昨 收 1.76
- 总市值 9246.83万
- 52周最高 2.9789
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.30
- 委 比 49.43%
- 总股本 5314.27万
- 历史最高 405.48
- 量 比 0.57
- 振 幅 7.10%
- 历史最低 1.30
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inovio Pharmaceuticals shares are trading lower after the FDA accepted the company's Biologics License Application for INO-3107 for review as a potential treatment for adults with RRP. The FDA Assigned INO-3107 A PDUFA review goal date of October 30, 2026 and that it is not currently planning to hold an advisory committee meeting to discuss the application.
Inovio Pharmaceuticals shares are trading lower after the FDA accepted the comp...
2025-12-29 22:21
FDA Accepts Inovio’s BLA for INO-3107 Review
Inovio Pharmaceuticals ( ($INO) ) has provided an announcement. On December 29,...
2025-12-29 21:47
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people fr...
2025-12-20 05:05
美股牛股 | Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%
Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%，与Coursera合并以扩大全球AI教育市场份额>>
2025-12-18 19:07
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and raises the price target from $5 to $6.
2025-11-15 00:06
Inovio Pharmaceuticals drops 6%, proposes equity offering
Inovio Pharmaceuticals (INO) proposed an underwritten public offering of its common stock, with all shares in the offering to be sold by the company itself. The underwriters have a 30-day option to pu...
2025-11-11 14:33
Inovio outlines mid-2026 launch for INO-3107 as BLA submission progresses
Earnings Call Insights: Inovio Pharmaceuticals (INO) Q3 2025 Management View CEO Jacqueline Shea highlighted, “we have achieved our primary objective for this year, which is completing the rolling sub...
2025-11-11 08:32
INOVIO Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
NOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
2025-11-11 07:14
Inovio Pharmaceuticals Q3 EPS $(0.87) Misses $(0.42) Estimate
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.42) by 105.67 percent. This is a 2.25 percent increase over losses of $(0.89) per
2025-11-11 05:03
